Zika virus T-cell based 704/DNA vaccine promotes protection from Zika virus infection in the absence of neutralizing antibodies
PLOS Neglected Tropical Diseases · 2024
DOI: 10.1371/journal.pntd.0012601 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Claude Roth und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ecology and Emergence of Arthropod-Borne Pathogens Unit, Institut Pasteur, CNRS UMR2000, 75015 Paris, France. Hauptthemen laut MEDLINE: Zika Virus Infection, Vaccines, DNA, Zika Virus, Antibodies, Neutralizing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Agence Nationale de la Recherche.
Abstract (Originalsprache)
Zika virus (ZIKV) and dengue virus (DENV) are closely related flaviviruses co-circulating in the same endemic areas. Infection can raise cross-reactive antibodies that can be either protective or increase risk of severe disease, depending on the infection sequence, DENV serotype and elapsed time between infection. On the contrast, T cell-mediated immunity against DENV and ZIKV is considered protective. Therefore, we have developed a T cell vaccine enriched in immunodominant T cell epitopes derived from ZIKV and evaluated its immunogenicity and efficacy against ZIKV and DENV infection. Mice were vaccinated using DNA vaccine platform using the tetrafunctional amphiphilic block copolymer 704. We show that vaccination of 2 different HLA class I transgenic mice with the ZIKV non-structural (NS) poly-epitope elicits T cell response against numerous ZIKV epitopes. Moreover, vaccination induces a significant protection against ZIKV infection, in the absence of neutralizing or enhancing antibodies against ZIKV. However, vaccination does not induce a significant protection against DENV2. In contrast, immunization with a DENV1-NS poly-epitope induces a significant protection against both DENV1 and DENV2, in the absence of humoral immunity. Taken together, we have shown that T-cell based vaccination could protect against multiple flavivirus infections and could overcome the complexity of antibody-mediated enhancement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ecology and Emergence of Arthropod-Borne Pathogens Unit, Institut Pasteur, CNRS UMR2000, 75015 Paris, France.
- Nantes Université, Univ Angers, INSERM, CNRS, Immunology and New Concepts in Immunotherapy, INCIT UMR1232/EMR6001, F-44000 Nantes, France.
- Immunology Unit, Institut Pasteur du Cambodge, Pasteur Network, Phnom Penh, Cambodia.
- Oxford University Clinical Research Unit, Ho Chi Minh, Vietnam.
ORCID-Profile: Claude Roth
Förderung
- NIAID NIH HHS
- Agence Nationale de la Recherche
Zitieren
APA
Roth, C., Pitard, B., Levillayer, L., Lay, S., Vo, H. T. M., Cantaert, T., & Sakuntabhai, A. (2024). Zika virus T-cell based 704/DNA vaccine promotes protection from Zika virus infection in the absence of neutralizing antibodies. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012601
Vancouver
Roth C, Pitard B, Levillayer L, Lay S, Vo HTM, Cantaert T, et al. Zika virus T-cell based 704/DNA vaccine promotes protection from Zika virus infection in the absence of neutralizing antibodies. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012601
BibTeX
@article{Roth2024,
author = {Roth, Claude and Pitard, Bruno and Levillayer, Laurine and Lay, Sokchea and Vo, Hoa Thi My and Cantaert, Tineke and Sakuntabhai, Anavaj},
title = {Zika virus T-cell based 704/DNA vaccine promotes protection from Zika virus infection in the absence of neutralizing antibodies},
journal = {PLOS Neglected Tropical Diseases},
year = {2024},
doi = {10.1371/journal.pntd.0012601}
}
EUVIMED